STOCK TITAN
  1. Home
  2. News
  3. ABOS

Acumen Pharmaceuticals, Inc. - $ABOS STOCK NEWS

Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: $ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acumen Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acumen Pharmaceuticals's position in the market.

News
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. will participate in a fireside chat at the UBS Biopharma Conference on Nov. 9, 2023. The company is developing a therapeutic for Alzheimer's disease targeting toxic soluble amyloid beta oligomers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.73%
Tags
conferences
-
News
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease
Rhea-AI Summary
Acumen Pharmaceuticals presents further analyses of the Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AβO-targeting antibody. The analyses reveal robust target engagement data modeling informing dose selection for the upcoming Phase 2/3 trial. New target engagement and pharmacokinetic analyses were also presented. Acumen plans to begin the Phase 2 portion of the study in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.84%
Tags
clinical trial
-
News
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
Rhea-AI Summary
Acumen Pharmaceuticals will present deeper insights and new findings from its Phase 1 INTERCEPT-AD trial evaluating ACU193 at the CTAD conference. ACU193 demonstrated a compelling overall safety profile and potential clinical benefit for early AD. The presentation will include data on dose-related target engagement, amyloid plaque reduction, and ARIA levels observed with ACU193 administration. The company believes ACU193 may offer a differentiated, next-generation treatment for Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences clinical trial
News
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
Rhea-AI Summary
Acumen Pharmaceuticals to participate in panel discussion at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
conferences
-
News
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
Rhea-AI Summary
Acumen Pharmaceuticals to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.4%
Tags
conferences
-
News
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported positive Phase 1 trial results for ACU193, a potential antibody treatment for early Alzheimer's disease. The trial showed rapid reduction of amyloid plaque and near-maximal target engagement of toxic amyloid beta oligomers (AβOs). The company raised $122 million in net proceeds through a public follow-on offering. They have cash and marketable securities of $172.2 million, expected to support clinical activities until the second half of 2026. A Phase 2 study is expected to start in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences earnings
-
News
Acumen Announces Pricing of Upsized $130 Million Public Offering
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announces the pricing of an upsized underwritten public offering of 16,774,193 shares of its common stock at $7.75 per share, expecting gross proceeds of approximately $130 million. The offering is expected to close on July 21, 2023. BofA Securities, Citigroup, and Stifel are acting as bookrunners for the public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.37%
Tags
offering
-
News
Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.7%
Tags
offering
News
Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease
Rhea-AI Summary
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will host a conference call and webcast today to discuss the positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, a novel therapeutic for Alzheimer's disease. The webcast will feature members of Acumen's leadership team, as well as renowned experts in the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
54.78%
Tags
clinical trial
Stock ABOS logo
Acumen Pharmaceuticals, Inc.

Nasdaq:ABOS

ABOS Rankings

#3705 Ranked by Market Cap
#5024 Ranked by Stock Gains
N/A Ranked by Dividends

ABOS Stock Data

224.10M
32.28M
9.13%
72.62%
2.06%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
CHARLOTTESVILLE

About ABOS

acumen is forging a new path towards safe and effective treatments for alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers. our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (aβo) in synaptic dysfunction and neurodegeneration. these early insights have fostered decades of research on the biology of aβo at acumen and throughout the field. we are now on the on cusp of realizing the therapeutic potential of aβo targeted drugs.